ABCURO

Newton, Massachusetts, March 11, 2025 - Abcuro, Inc., a clinical-stage biotechnology company developing therapies for the treatment of autoimmune diseases and cancer through precise modulation of cytotoxic T cells, today announced that the Company will present safety, pharmacokinetic, and pharmacodynamic data from the Phase 1 clinical trial evaluating ulviprubart (ABC008) for the treatment of inclusion... Precision Targeting of Highly Cytotoxic T Cells in Autoimmune Disease.

Also known as: Abcuro, Inc.

Primary location: Newton United States